Becton, Dickinson and Company (BDX)

Market Cap	68.84B
Revenue (ttm)	20.18B
Net Income (ttm)	1.71B
Shares Out	290.01M
EPS (ttm)	5.86
PE Ratio	40.51
Forward PE	16.52
Dividend	$4.16 (1.75%)
Ex-Dividend Date	Dec 9, 2024

Volume	1,660,543
Open	236.51
Previous Close	236.30
Day's Range	235.44 - 238.49
52-Week Range	218.75 - 248.42
Beta	0.42
Analysts	Strong Buy
Price Target	283.50 (+19.43%)
Earnings Date	Feb 6, 2025

About BDX

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• IPO Date: Apr 23, 1962
• Employees: 73,000
• Stock Exchange: NYSE
• Ticker Symbol: BDX
• Website: https://www.bd.com

Financial Performance

In 2024, BDX's revenue was $20.18 billion, an increase of 4.16% compared to the previous year's $19.37 billion. Earnings were $1.71 billion, an increase of 19.73%.

Analyst Forecast

According to 6 analysts, the average rating for BDX stock is "Strong Buy." The 12-month stock price forecast is $283.5, which is an increase of 19.43% from the latest price.

Price Target

$283.5

(19.43% upside)

Analyst Consensus: Strong Buy